Anthropic launches Claude for Life Sciences, its first specialized AI platform for the sector, promising to slash research tasks from days to minutes by integrating with scientific tools like PubMed and Benchling to accelerate discovery from literature reviews to regulatory submissions.
Cortical Labs launches CL1, the world's first commercial biological computer that harnesses 800,000 lab-grown human neurons to process data with submillisecond response times, offering a $35,000 energy-efficient alternative to traditional computing for pharmaceutical, financial, and AI research applications.
Google's new 27 billion parameter AI model discovers that combining silmitasertib with low-dose interferon can convert immune-resistant 'cold' tumors into 'hot' targets for immunotherapy, with lab tests confirming a 50% boost in immune recognition.
Billionaire Mark Cuban harnesses OpenAI's Sora platform to generate AI videos of himself promoting his pharmaceutical company Cost Plus Drugs, with the viral clips featuring him delivering promotional messages and dancing garnering tens of thousands of views as a cost-free marketing experiment.
Google enhances its Jules AI coding assistant with new command line tools and API support, while Nvidia introduces a revolutionary 4-bit training format that cuts AI training costs, and MIT researchers use generative AI to dramatically accelerate antibiotic discovery from years to much shorter timeframes.
AstraZeneca strikes a massive $555 million partnership with Algen Biotechnologies, combining cutting-edge AI platform 'AlgenBrain' with CRISPR gene technology to revolutionize drug discovery for chronic inflammatory diseases and unlock next-generation immunology therapies.
MIT and McMaster University researchers use AI to discover enterololin, a revolutionary narrow-spectrum antibiotic that targets harmful gut bacteria causing Crohn's disease while preserving beneficial microbes, showing promising results in mouse studies and advancing toward human trials.
RNA structure prediction remains far behind protein prediction as AlphaFold3 struggles with RNA's extreme flexibility, with only 7,759 RNA structures mapped versus 216,212 proteins, though most RNA therapeutics like mRNA vaccines rely on secondary structure which scientists can now predict with high accuracy.
Eli Lilly unveils TuneLab, an AI-driven drug discovery platform backed by a $1 billion research investment, offering biotech companies access to AI models built on Lilly's extensive drug data and joining Lilly Catalyze360's offerings for biotech partners.
Researchers harness AI to uncover abaucin, a groundbreaking antibiotic disrupting lipoprotein trafficking, offering a potent weapon against drug-resistant Acinetobacter baumannii bacteria, sparking hope for treating stubborn wound infections.